Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma
Open Access
- 1 July 2020
- journal article
- research article
- Published by Future Medicine Ltd in Future Oncology
- Vol. 16 (20), 1441-1454
- https://doi.org/10.2217/fon-2020-0314
Abstract
Aim: To determine outcomes of retreatment with anti-PD-1 monotherapy for melanoma. Materials & methods: This retrospective study included adults with unresectable cutaneous melanoma who achieved stable disease (SD) or better after anti-PD-1 monotherapy and were retreated with anti-PD-1 monotherapy after >= 90-day gap. We determined overall survival and real-world tumor response. Results: For 21 eligible patients, from retreatment initiation, median follow-up was 14.4 months (range, 2.6-34.5); median overall survival was 30.0 months (95% CI: 14.4-not reached); 1-year survival was 100% (95% CI: 100-100%); 2-year survival was 83% (48-96%). Of 16 patients with recorded best real-world tumor response, ten (63%) responded (complete/partial response); three achieved SD; three had progressive disease. Conclusion: Patients with advanced melanoma achieving SD/better after first-course anti-PD-1 monotherapy may benefit from retreatment.This publication has 33 references indexed in Scilit:
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With NivolumabJAMA Oncology, 2019
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyThe Lancet Oncology, 2019
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaAnnals of Oncology, 2019
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2018
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerationsJournal for ImmunoTherapy of Cancer, 2018
- The cessation of anti-PD-1 antibodies of complete responders in metastatic melanomaMelanoma Research, 2017
- Opportunities and challenges in leveraging electronic health record data in oncologyFuture Oncology, 2016
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- Cutaneous melanomaThe Lancet, 2014
- Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma RegistryJournal of the American Academy of Dermatology, 2012